References
- Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022 Oct 25;328(16):1604–1615. doi: 10.1001/jama.2022.18931
- Wulf Hanson S, Abbafati C, Aerts JG, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. medRxiv. 2022 May 27. doi: 10.1101/2022.05.26.22275532
- Shaffer L. Lots of long COVID treatment leads, but few are proven. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2213524119. doi: 10.1073/pnas.2213524119
- Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep;114(9):428–442.
- Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133–146.
- Chee YJ, Fan BE, Young BE, et al. Clinical trials on the pharmacological treatment of long COVID: a systematic review. J Med Virol. 2023 Jan;95(1):e28289.
- Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022 Jun 10;3(6):371–387 e9. doi: 10.1016/j.medj.2022.04.001
- Geng LN, Bonilla HF, Shafer RW, et al. The use of nirmatrelvir-ritonavir in a case of breakthrough long COVID. Explor Res Hypothesis Med. 2023; doi: 10.14218/ERHM.2022.00045
- Simonin Y. Neurobiology of long-COVID: hypotheses and unanswered questions. Anaesth Crit Care Pain Med. 2023 Feb 15;42(3):101201. doi: 10.1016/j.accpm.2023.101201
- Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023 Feb 8;76(3):e487–e490. doi: 10.1093/cid/ciac722
- de Melo GD, Lazarini F, Levallois S, et al. COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021 Jun 2;13(596). doi: 10.1126/scitranslmed.abf8396
- Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022 Aug;163(2):495–506 e8.
- Angeli F, Reboldi G, Trapasso M, et al. COVID-19, vaccines and deficiency of ACE(2) and other angiotensinases. Closing the loop on the “Spike effect”. Eur J Intern Med. 2022 Sep;103:23–28.
- Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post−COVID-19 condition. JAMA Intern Med. 2023 Mar 23;183(6):566. doi: 10.1001/jamainternmed.2023.0750
- Haroon S, Nirantharakumar K, Hughes SE, et al. Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study). BMJ Open. 2022 Apr 26;12(4):e060413. doi: 10.1136/bmjopen-2021-060413